Charles River Laboratories (CRL) 13F Holdings Overview (Q2 2026)

CRL ranks #1018 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

CRL is a disclosed holding of Bill Nygren (Harris Associates L.P.), one of the tracked superinvestors on AlphaSMO — it makes up 0.7% of that fund's own 13F portfolio.

568 institutions disclose a position in CRL, but none treat it as a major bet — even Ariel Investments, LLC, its most concentrated holder, allocates just 3.4% of its own portfolio to it.

Fidelity has added to its CRL position for two straight quarters, increasing it by $615.7M to reach $961.5M today.

Mackenzie Financial CORP has trimmed its CRL position for two straight quarters, cutting it by $157.2M while still holding $350.6K.

CRL is up 3.3% today, and institutions have been net buyers of $2.5B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CRL reported a net loss of $238.5M over the trailing twelve months.

• Not yet profitable — net loss of $238.5M over the trailing twelve months
• Revenue declined 0.6% year over year
• Net income declined year over year, from -$25.3M to -$238.5M
• Generated $737.6M in positive operating cash flow
• Current ratio of 1.29x — below the conventional 1.5x liquidity buffer
• Liabilities run 1.24x equity — within a conventional range